Microtubules and actin filaments: Dynamic targets for cancer chemotherapy

Current Opinion in Cell Biology

Volumn 10, Issue 1, 1998, Pages 123-130

  Jordan, Mary Ann ^a   Wilson, Leslie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTIMITOTIC AGENT; BETA TUBULIN; BISTHEONELLIDE A; CRYPTOPHYCIN; CYTOCHALASIN; DISCODERMOLIDE; EPOTHILONE A; JASPAMIDE; NATURAL PRODUCT; ONCOPROTEIN; ONCOPROTEIN 18; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ACTIN FILAMENT; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CYTOSKELETON; MICROTUBULE; PRIORITY JOURNAL; REVIEW;

EID: 0032006059     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(98)80095-1     Document Type: Article

References (97)

1. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darnell J. edn 3 Mol Cell Biol. 1995;Scientific American Books, New York.
2. Mitchison TJ, Kirschner M. Dynamic instability of microtubule growth. Nature. 312:1984;237-242.
3. Margolis RL, Wilson L. Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell. 13:1978;1-8.
4. Margolis RL, Wilson L. Microtuble treadmills-possible molecular machinery. Nature. 293:1981;705-711.
5. Rodionov VI, Borisy GG. Microtubule treadmilling in vivo. of special interest Science. 275:1997;215-218 This paper contains an elegant demonstration of rapid microtubule treadmilling in melanophore cell cytoplasts preparations in the absence of delectable dynamic instability behavior.
6. Waterman-Storer CM, Salmon ED. Microtubule dynamics: treadmilling comes around again. of special interest Curr Biol. 7:1997;369-372 This paper summarizes recent data on microtubule treadmilling in living cells.
7. Wang Y-L. Exchange of actin subunits in the leading edge of living fibroblasts: possible of treadmilling. J Cell Biol. 101:1985;597-602.
8. Theriot JA, Mitchison TJ. Actin microfilament dynamics in locomoting cells. Nature. 352:1991;126-131.
9. Hayden JJ, Bowser SS, Rieder C. Kinetochores capture astral microtubules during chromosomes attachment to the mitotic spindle: direct visualization in live newt cells. J Cell Biol. 111:1990;1039-1045.
10. Rieder CL, Alexander SP, Rupp G. Kinetochores are transported poleward along a single astral microtubule during chromosome attachment to the spindle. J Cell Biol. 110:1990;81-95.
11. Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol. 2:1995;569-573.
12. Theriot JA. Accelerating on a treadmill: ADF/cofilin promotes rapid actin filament turnover in the dynamic cytoskeleton. of outstanding interest J Cell Biol. 136:1997;1165-1168 This paper describes, in summary form, the results of recent papers showing that the dynamics of actin filaments are much more rapid in cells than in vitro, and that the rapid dynamics are promoted by a group of small actin binding proteins including cofilin, destrin, depactin, actophorin, and actin depolymerizing factor (ADF).
13. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblasts cells. Proc Natl Acad Sci USA. 77:1980;1561-1565.
14. Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51:1991;4845-4852.
15. Hung DT, Chen J, Schrieber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. of special interest Chem Biol. 3:1996;287-293 Here, the authors report that discodermolide competes with taxol for binding to microtubules and binds with higher affinity than taxol. It also induces M phase arrest and bundles microtubles in cells.
16. Ter Haar E, Kowalski R, Hamel E, Lin C, Longley R, Gunasekera S, Rosenkranz H, Day BW. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. of special interest Biochemistry. 35:1996;243-250 In the paper it is shown that discodermolide is a cytotoxic marine agent that induces mitotic arrest in Burkitt lymphoma cells, bundles microtubules in cells, and is more potent than taxol in inducing tubulin to form microtubules at low temperature, in the absence of GTP and/or microtubule binding proteins.
17. Kowalski R, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). of special interest J Biol Chem. 272:1997;2534-2541 This paper shows that epothilones A and B block mitosis, induce tubulin to form microtubules at low temperature in the absence of GTP and/or microtubule binding proteins, and competitively inhibit the binding of taxol to tubulin polymers. Epothilone B is shown to be more potent in cells than epothilone A or taxol. Drug-resistant colon and ovarian cell lines retain sensitivity to the epothilones.
18. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA. 90:1993;9552-9556.
19. Dhamodharan RI, Jordan MA, Thrower D, Wilson L, Wadsworth P. Vinblastine suppresses dynamics of individual microtubules in living cells. Mol Biol Cell. 6:1995;1215-1229.
20. Panda D, Jordan MA, Chin K, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem. 271:1996;29807-29812.
21. Panda D, Daijo JE, Jordan MA, Wilson L. Kinetic stabilization of microtubule dynamics at steady state in vitro by substoichiometric concentrations of tubulin-colchicine complex. Biochemistry. 34:1995;9921-9929.
22. Panda D, Himes D, Himes RH, Moore RE, Wilson L, Jordan MA. Unusually potent suppression of microtubule dynamics by crytophycin 1: a mechanism for its antiproliferative action. Biochemistry. 36:1997;12948-12953.
23. Vasquez RJ, Howell B, Yvon A-MC, Wadsworth P, Cassimeris L. Nanomolar concentrations on nocodazole alter microtubule dynamic instability in vivo and in vitro. of special interest Mol Biol Cell. 8:1997;973-985 Here the authors show that he compound nocodazole, a benzimidazole derivative that arrests mitosis, suppresses microtubule dynamics in living cells in interphase without depolymerizing microtubules.
24. Panda D, Miller H, Islam K, Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action. of special interest Proc Natl Acad Sci USA. 94:1997;10560-10564 Shows additive stabilization of microtubule dynamics by low concentrations on vinblastine and estramustine.
25. Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry. 34:1995;2203-2211.
26. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 51:1991;2212-2222.
27. Zhang D, Nicklas R. Chromosomes initiate spindle assembly upon experimental dissolution of the nuclear envelope in grasshopper spermatocytes. J Cell Biol. 131:1995;1125-1131.
28. Wendell KL, Wilson L, Jordan MA. Mitotic block in HeLa cells by vinblastine: ultrastructural changes in kinetochore-microtubule attachment and in centrosomes. J Cell Sci. 104:1993;261-274.
29. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 102:1992;401-416.
30. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplications in the absence of p53. of special interest Science. 271:1996;1744-1747 In this paper it is observed that in mouse embryonic fibroblasts lacking the p53 tumor suppressor protein, multiple copies of functionally competent centrosomes were generated during a single cell cycle, implicating p53 in the regulation of centrosome duplication and suggesting a mechanism by which loss of p53 may cause genetic instability.
31. Waters JC, Mitchison TJ, Rieder CL, Salmon ED. The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. of special interest Mol Biol Cell. 7:1996;1547-1558 Here the authors show that taxol inhibits kinetochore-microtubule assembly/disassembly at kinetochores; however, minus-end microtubule disassembly continued.
32. Derry WB, Wilson L, Jordan MA. The low potency of taxol at microtubule minus ends: implications for its therapeutic mechanism. Cancer Res. 1998;. in press.
33. Li X, Nicklas RB. Mitotic forces control a cell-cycle checkpoint. Nature. 373:1995;630-632.
34. Nicklas RB, Ward SC, Gorbsky GJ. Kinetochore chemistry is sensitive to tension and may link mitotic forces to a cell cycle checkpoint. J Cell Biol. 130:1995;929-939.
35. Rieder CL, Cole RW, Khodjakov A, Sluder G. The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetchores. J Cell Biol. 130:1995;941-948.
36. Chen R, Waters J, Salmon E, Murray A. Association of spindle assembly checkpoint component XMAD2 with unattached kinetochores. of outstanding interest Science. 274:1996;242-246 This paper reports the isolation and expression of a cDNA encoding the Xenopus homolog of MAD2 protein (mitotic-arrest deficient 2 protein). Affinity-purified antibodies to XMAD2 recognized a 25-kD protein localized to unattached kinetochores at prometaphase in nocodazole-treated frog or human cells. The protein disappeared from kinetochores at metaphase in untreated cells, suggesting that XMAD2 plays a role in activation of the checkpoint by unattached kinetochores.
37. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. of outstanding interest Science. 274:1996;249-249 Here, the human homolog of MAD2 (hsMAD2) was isolated and shown to be a necessary component of nocodazole-induced mitotic arrest in Hela cells, by electroporation of anti-hsMAD2 antibodies. As in [36], hsMAD2 was localized at the kinetochore in prometaphase in nocodazole-treated cells, but disappeared from kinetochores at metaphase in untreated cells. Human breast tumor cells exhibited reduced hsMAD2 expression and failed to arrest in mitosis after nocodazole treatment, suggesting that defects in MAD2 expression may alter the responsiveness of tumors to antimitotic drugs.
38. Minshull J, Straight A, Rudner AD, Demburg AF, Belmont A, Murray AW. Protein phosphatase 2A regulates MPF activity and sister chromatid cohesion in budding yeast. of special interest Curr Biol. 6:1996;1609-1620 In this paper it is shown that in budding yeast the cdc55 gene, which encodes a protein phosphatase 2A regulatory subunit, shows a checkpoint defect that allows sister chromatids to separate and cells to exit mitosis without inducing cyclin B destruction. This suggests that after drug-blockage at the mitotic checkpoint, cells may bypass the cyclin B proteolytic mechanism and inactivate MPF by phosphorylation of Cdc28.
39. Straight A, Belmont A, Robinett CC, Murray AW. GFP tagging of budding yeast chromosomes reveals that protein - protein interactions can mediate sister chromatid cohesion. of special interest Curr Biol. 6:1996;1599-1608 In mitotic checkpoint-deficient yeast mutants mad and bub, this study shows sister chromatid separation can occur in the absence of microtubules (after microtubule depolymerization by high concentrations of the mitotic inhibitor nocodazole), indicating that sister chromatic separation is under the control of the spindle-assembly checkpoint and can occur in the absence of microtubule-dependent forces.
40. Rudner AD, Murray AW. The spindle assembly checkpoint. Curr Biol. 8:1996;773-780.
41. McEwen B, Heagle A, Cassels G, Buttle K, Rieder C. Kinetochore fiber maturation in PtK1 cells and its implications for the mechanisms of chromosome congression and anaphase onset. of outstanding interest J Cell Biol. 137:1997;1567-1580 By same-cell video light microscopy/serial section electron microscopy of PtK1 cells the authors of this report found that treatment of late metaphase cells with 1 μM taxol inhibits anaphase onset, but does not alter the number of kinetochore microtubules, suggesting that inhibition of anaphase onset by taxol involves suppression of microtubule dynamics rather than inhibition of microtubule attachment to kinetochores.
42. Colombel M, Olsson CA, Ng PY, Buttyan R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res. 52:1992;4313-4319.
43. Jordan MA, Wendell KL, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentration of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. of special interest Cancer Res. 56:1996;816-825 In this paper the authors triggered apoptosis in HeLa cells, following mitotic block, by low nanomolar concentations of taxol that appear to suppress microtubule dynamics but do not bundle microtubules. Following removal of taxol, cells entered an interphase-like state without progressing through anaphase or cytokinesis and underwent apoptosis.
44. Bhalla K, Ilerado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 7:1993;563-568.
45. Donaldson KL, Goolsby G, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ. 5:1994;1041-1050.
46. Danesi R, Figg WD, Reed E, Myers CE. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol. 47:1995;1106-1111.
47. Martin SJ, Cotter TG. Disruption of microtubules induces an endogenous suicide pathway in human leukaemia HL-60 cells. Cell Tissue Kinet. 23:1990;545-559.
48. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1:1995;1076-1551.
49. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers L. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. of special interest Cancer Res. 56:1996;1851-1854 In this paper the authors demonstrate taxol-induced phosphorylation and activation of the Raf-1 mitogen-stimulated protein kinase, coincident with phosphorylation of bcl-2. Depletion of Raf-1 protein by benzoquinone ansamycin GA prevented taxol-induced apoptosis and bcl-2 phosphorylation.
50. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DGI, Higgs PL, Neckers L, Fojo T. Raf-1/bcl2 phosphorylation: a step from microtubule damage to cell death. of special interest Cancer Res. 57:1997;130-135 Here, it is reported that to taxol, vinca alkaloids, colchicine, epothilones and other microtubule active agents induce Raf-1/bcl-2 phosphorylation.
51. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. of special interest Cancer Res. 57:1997;229-233 The authors of this report observed that drugs that affect microtubules, including taxotere (1-100 nM), vinblastine, and vincristine (100 nM), induce phosphorylation of bcl2 in G2/M and induce apoptosis in human leukemia, lymphoma, breast and prostate cancer cells.
52. Trielli M, Andreasson PR, Lacroix FB, Margolis RL. Differential taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. of special interest J Cell Biol. 135:1996;689-700 In this paper evidence is presented showing that taxol, but not nocodazole, at micromolar concentrations, may induce a G1 block from which nontransformed rat and human fibroblasts recover and proliferate after release from taxol; however, transformed cells of the same lineage slip through the checkpoint and undergo apoptotis. The results suggest the existence of a microtubule-dependent checkpoint in G1 which is abrogated in transformed cells.
53. Di Leonardo A, Khan S, Linke S, Greco V, Seidita G, Wahl G. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. of special interest Cancer Res. 57:1997;1013-1019 This group found that normal mouse and human fibroblasts arrested with a 4N DNA content when treated with nocodazole and Colcemid, whereas isogeneic p53-deficient or pRb-deficient derivatives became polyploid indicating different susceptibilities of normal and mutated cells to anti-mitotic drugs.
54. Ter Harr E, Hamel E, Balachandran R, Day B. Cellular targets of the anti-breast cancer agent Z-1, 1-dichloro-2,3-diphenylcyclopropane; type II estrogen binding sites and tubulin. Anticancer Res. 17:1997;1861-1869.
55. Zhang X, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol Pharmacol. 49:1996;288-294.
56. Panda S, Singh JP, Wilson L. Suppression of microtubule dynamics by LY290181. J Biol Chem. 272:1997;7681-7687.
57. Wood DL, Panda D, Wiernicki TR, Wilson L, Jordan MA, Singh JP. Inhibition of mitosis and microtubule function through direct tubulin binding by a novel antiproliferative naphthopyran LY290181. Mol Pharmacol. 52:1997;437-444.
58. Kruczynski A, Barret J-M, Etievant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin interacting properties of a novel fluorinated vinca alkaloid, vinflunine. Biochem Pharmacol. 1997;. in press.
59. Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E. Characterization of the interaction of crytophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition to dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res. 56:1996;4398-4406.
60. Smith CD, Zhang X. Mechanism of action of cryptophycin. Interaction with the vinca alkaloid domain of tubulin. J Biol Chem. 271:1996;6192-6196.
61. Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH. Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Letts. 377:1995;59-61.
62. Photiou A, Shah P, Leong L, Moss J, Retsas S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. of special interest Eur J Cancer. 33:1997;463-470 Here the authors report that adding taxol and vinorelbine, a synthetic vinca alkaloid, at low nanomolar concentrations concurrently to cultures of human melanoma cell lines, resulted in supra-additive or synergistic antiproliferative effects.
63. Garcia P, Braguer D, Carles G, Briand C. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anti-Cancer Drug. 6:1995;533-544.
64. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 52:1992;4433-4440.
65. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics and microtubules assembled from unfractionated and purified beta-tubulin isotypes. of special interest Biochemistry. 36:1997;3554-3562 In this report the authors report that microtubules composed of purified αβ III or αβIV bovine brain tubulin were sevenfold less sensitive to the suppressive effects of bound taxol on the rate of shortening during excursions of dynamic instability, suggesting that cellular expression of increased levels of βIII or βIV tubulin isotypes may be an important mechanism of tumor cell resistance to taxol.
66. Laing N, Dahllof B, Hartley-Asp B, Ranganathan S, Tew KD. Interaction of estramustine with tubulin isotypes. of special interest Biochemistry. 36:1997;871-878 This paper documents the finding that binding of estramustine to the βIII isotype of tubulin occurs with reduced efficacy as compared with other β-tubulin isotypes, thus suggesting a mechanism for the resistance to estramustine of cancer cells overexpressing the βIII isotype of tubulin (see reference [69]).
67. Kavalleris M, Kuo DY-S, Burkhardt CA, Regl DL, Norris MD, Haber M, Horwitz SB. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 100:1997;1-12 In this report the authors observed that taxol-resistant human ovarian tumors displayed significant increases in expression of class I, III and IVa β-tubulins, when compared to untreated primary ovarian tumors. Taxol-resistant cultured human lung cancer cells are also showed increases in the levels of classes, I,II,III, and IVa β tubulins, although MDR expression, total tubulin levels, and drug.
68. Jaffrezou J-P, Dumontet C, Derry WB, Duran G, Tsuchiya E, Wilson L, Jordan MA, Sikic B. Novel mechanism of resistance of paclitaxel in human K562 leukemia cells by combined selection with PSC833. Oncology Res. 7:1995;517-527.
69. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew K, Hudes GR. Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. of special interest Cancer Res. 56:1996;2584-2589 The authors of this paper report that human prostate carcinoma cells (DU145), selected for resistance to estramustine, were moderately cross-resistant to paclitaxel, and overexpressed two β-tubulin isotypes three- to fourfold (classes IVa and III), suggesting that altered expression of tubulin isotypes may play a role in cellular resistance to antimicrotubule drugs.
70. Dumontet C, Duran G, Steger K, Beketic-Oreskovic L, Sikic B. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). of special interest Cancer Res. 56:1996;1091-1097 In this report single-step exposure of MES-SA sarcoma cells to paclitaxel induced formation of 5 Mdr1-negative clones that were resistant to taxol, cross-resistant to vinca alkaloids, and underexpressed 2 β-tubulin isotypes, β5 (class IVa) and β4 (class III), as determined by RT-PCR, which suggests that altered microtubule function is responsible for resistance to taxol in these cells.
71. Giannakakou P, Sackett D, Kang Y, Zhan Z, Buters J, Fojo T, Poruchynsky M. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. of outstanding interest J Biol Chem. 272:1997;17118-17125 Here, the authors report that purified tubulin from two taxol-resistant sublines of human ovarian carcinoma cells exhibited resistance to taxol-induced polymerization which was attributed to acquired point mutations in the M40 isotype. The cell lines were sensitive to vinblastine, accumulated paclitaxel equally with the parental cells, expressed no detectable MDR-1 RNA, and expressed β-tubulin isotypes similarly, with a 1-5-fold increase in expression of M40 (betal) RNA.
72. Cabral F, Barlow SB. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J. 3:1989;1593-1599.
73. Horwitz S, Shen H, He L, Dittmar P, Neef R, Chen J, Schubart U. The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation. of special interest J Biol Chem. 272:1997;8129-8132 In this experiment, microinjection of recombinant Op18 induced disassembly of microtubules in cells and in vitro. Aspartate substitution of a single serine residue (Ser63) abolished the effect on cellular microtubules.
74. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin and increases the catastrophe rate of microtubules. of special interest Cell. 84:1996;623-631 This report documents the purification of OP18 from calf thymus extracts and the finding that it is a 17 kDa protein that it appears to bind tubulin dimers; destabilize microtubules, increase their catastrophe rates and decrease their growth rates. OP18 inhibited the taxol (300 μM)-induced polymerization of microtubules. OP18 is therefore a plausible regulator of microtubule dynamics during the cell cycle.
75. Marklund U, Larsson N, Graden H, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. of special interest EMBO J. 15:1996;5290-5298 In this paper it is reported that increased expression of Op 18 resulted in microtubule depolymerization in interphase cells, but mitotic spindles were normal. Expression of Op18 mutated at serines 25 and 38 resulted in an absence of mitotic microtubules.
76. 2+/calmodulin-dependent kinase IV/Gr can suppress the microtubule regulating activity of Op18. Increased phosphorylation of Op 18 on serine residue 16 is associated with partial degradation of Op18 and an increase in cellular microtubule mass.
77. Janmey PA, Chaponnier C. Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol. 7:1995;111-117.
78. Sigmond SH. Signal transduction and actin filament organization. Curr Opin Cell Biol. 8:1996;66-73.
79. Tapon N, Hall A. Rho, Rac, and Cdc42 GTPases regulate the organizational of the actin cytoskeleton. Curr Opin Cell Biol. 9:1997;86-92.
80. Assoian RK, Zhu X. Cell anchorage and the cytoskeleton as partners in growth factors dependent cell cycle progression. Curr Opin Cell Biol. 9:1997;93-98.
81. Stournaras C, Stiakaki E, Koukouritaki SB, Theodoropoulos PA, Kalmanti M, Fostinis Y, Gravanis A. Altered actin polymerization dynamics in various malignant cell types: evidence for different sensitivity to cytochalasin B. of outstanding interest Biochem Pharmacol. 52:1996;1339-1346 In this report the soluble: total actin ratio of maligant cells was found to be 1.37 to 1.81-fold higher than that of normal cells. The viability of maligant cells was also shown to be more strongly affected by cytochalasin B.
82. Hermstreet GP III, Rao JY, Hurst RE, Bonner RB, Waliszewski P, Grossman HB, Liebert M, Bane B. G-actin as a risk factor and modulatable endpoint for cancer prevention trials. of outstanding interest J Cell Biochem. 25S:1996;197-204 This review article describes evidence indicating that increased levels of unpolymerized actin and decreased levels of polymerized actin accompany development of cancer and that the soluble and polymeric actin levels in cells may be an important biomarker for early detection of cancer.
83. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL, Asch BB. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. of outstanding interest Cancer Res. 56:1996;4841-4845 This paper expands on previous work showing decreased levels of gelsolin in tumor cells. Gelsolin was shown to be absent or greatly reduced in 70% of human breast cancers and in 100% of rat and mouse primary mammary tumors examined. The authors draw the potentially important conclusion that - across three species - partial or complete loss of gelsolin expression is one of the most frequently occurring defects in breast cancer, regardless of etiology. Insufficient gelsolin may impair regulation of the actin filament cytoskeleton and impair various signal transduction pathways involving the actin cytoskeleton, thereby leading to growth and behavioral defects in breast cancer cells by changing their response to external signals.
84. Tanenbaum SW. Cytochalasins, Biochemical and Cell Biological Aspects. 1978;North Holland Publishing Company, Amsterdam.
85. Cooper JA. Effects of cytochalasin and phalloidin on actin. J Cell Biol. 105:1987;1473-1477.
86. Spector I, Shochet NR, Blasberger D, Kashman Y. Lantrunculins - novel marine macrolides that disrupt microfilament organization and accct cell growth: 1. Comparison with cytochalasin D. Cell Motil Cytoskeleton. 13:1989;127-144.
87. Ayscough KR, Stryker J, Pokala N, Sanders M, Crews P, Drubin DG. High rates of actin filament turnover in budding yeast and roles for actin is establishment and maintenance of cell polarity revealed using the actin inhibitor lantrunculin-A. of outstanding interest J Cell Biol. 137:1997;399-416 This paper reports that the actin assembly-inhibitor lantrunculin A caused complete disruption of actin cytoskeleton in budding yeast within 2-5 min of addition, indicating that the actin cytoskeleton in this non-motile organism is highly dynamic. The study revealed the importance of actin dynamics in a number of yeast cell processes, including localization of secretory vesicles during localized exocytosis.
88. Bubb MR, Senderowicz AMJ, Duncan KIK, Korn ED. Jasplakinolide, a cytotoxic natural product induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem. 269:1994;14869-14871.
89. Senderowicz AM, Kaur G, Sainz E, Laing C, Inman WD, Rodriguez J, Crews P, Malspeis L, Grever MR, Sausville EA, et al. Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J Natl Cancer Inst. 87:1995;46-51.
90. Bubb MR, Spector I, Bershadsky AD, Kom ED. Swimholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments. J Biol Chem. 270:1995;3463-3466.
91. Terry DR, Spector I, Higa T, Bubb MR. Misakinolide A is a marine macrolide that caps but does not sever filamentous actin. J Biol Chem. 272:1997;7841-7845.
92. O'Brien ET, Asai DJ, Jacobs RS, Wilson L. Selective inhibition of cytokinesis in sea urchin embryos by low concentrations of stypoldione, a marine natural product that reacts with sulfhydryl groups. Ann Biochem. 181:1989;51-58.
93. Grace KJS, Medina M, Jacobs RS, Wilson L. Selective inhibition of cytokinesis in sea urchin embryos by the marine natural product pseudopterolide. Mol Pharmacol. 4:1992;631-638.
94. L, is independent of p53 status, and is inhibited by a myristylated form of RhoB.
95. Predergast GC, Davide JP, deSolms SJ, Giuliani E, Graham S, Gibbs J, Oliff A, Kohl NE. Farnesytransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 14:1994;4193-4202.
96. Predergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 56:1996;2626-2632.
97. Gibbs J, Liff A. The potential of farnesyltransferase inhibitors as cancer chemotherpeutics. Annu Rev Pharmacol Toxicol. 37:1997;143-166.